KRYS Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of 49.9% compared to Krystal Biotech's net margin of 16.72%. Krystal Biotech's return on equity of 10.49% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Krystal Biotech has a consensus price target of $214.80, signalling upside risk potential of 30.18%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.77 which suggests that it could grow by 70.3%. Given that Biomarin Pharmaceutical has higher upside potential than Krystal Biotech, analysts believe Biomarin Pharmaceutical is more attractive than Krystal Biotech.

Krystal Biotech has a beta of 0.751, which suggesting that the stock is 24.867% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.302, suggesting its less volatile than the S&P 500 by 69.812%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $91.1M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Krystal Biotech's net income of $45.5M is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, Krystal Biotech's price-to-earnings ratio is 55.18x while Biomarin Pharmaceutical's PE ratio is 25.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 16.87x versus 3.95x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of 49.9% compared to Krystal Biotech's net margin of --. Krystal Biotech's return on equity of 10.49% beat Perspective Therapeutics's return on equity of --.

Krystal Biotech has a consensus price target of $214.80, signalling upside risk potential of 30.18%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 638.1%. Given that Perspective Therapeutics has higher upside potential than Krystal Biotech, analysts believe Perspective Therapeutics is more attractive than Krystal Biotech.

Krystal Biotech has a beta of 0.751, which suggesting that the stock is 24.867% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $91.1M, which are larger than Perspective Therapeutics quarterly revenues of --. Krystal Biotech's net income of $45.5M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Krystal Biotech's price-to-earnings ratio is 55.18x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 16.87x versus 12.62x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Mirum Pharmaceuticals has a net margin of 49.9% compared to Krystal Biotech's net margin of -23.93%. Krystal Biotech's return on equity of 10.49% beat Mirum Pharmaceuticals's return on equity of -37.59%.

Krystal Biotech has a consensus price target of $214.80, signalling upside risk potential of 30.18%. On the other hand Mirum Pharmaceuticals has an analysts' consensus of $63.78 which suggests that it could grow by 61.14%. Given that Mirum Pharmaceuticals has higher upside potential than Krystal Biotech, analysts believe Mirum Pharmaceuticals is more attractive than Krystal Biotech.

Krystal Biotech has a beta of 0.751, which suggesting that the stock is 24.867% less volatile than S&P 500. In comparison Mirum Pharmaceuticals has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.33300000000001%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. Mirum Pharmaceuticals pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $91.1M, which are smaller than Mirum Pharmaceuticals quarterly revenues of $99.4M. Krystal Biotech's net income of $45.5M is higher than Mirum Pharmaceuticals's net income of -$23.8M. Notably, Krystal Biotech's price-to-earnings ratio is 55.18x while Mirum Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 16.87x versus 6.13x for Mirum Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 49.9% compared to Krystal Biotech's net margin of -49.65%. Krystal Biotech's return on equity of 10.49% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Krystal Biotech has a consensus price target of $214.80, signalling upside risk potential of 30.18%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 60.41%. Given that NovaBay Pharmaceuticals has higher upside potential than Krystal Biotech, analysts believe NovaBay Pharmaceuticals is more attractive than Krystal Biotech.

Krystal Biotech has a beta of 0.751, which suggesting that the stock is 24.867% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $91.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Krystal Biotech's net income of $45.5M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Krystal Biotech's price-to-earnings ratio is 55.18x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 16.87x versus 0.14x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.